Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ISCHSTR
MCID: STR067
MIFTS: 80

Stroke, Ischemic (ISCHSTR)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Stroke, Ischemic

About this section

MalaCards integrated aliases for Stroke, Ischemic:

Name: Stroke, Ischemic 56 40 37
Cerebral Infarction 56 40 12 73 54 43 15 71 32
Stroke 56 53 54 6 42 3 62 17
Ischemic Stroke 56 73 29 6 42 71
Cerebrovascular Accident 56 40 73 71
Cerebral Infarction, Susceptibility to 56 13 6
Stroke, Ischemic, Susceptibility to 56 29 39
Ischemic Stroke, Susceptibility to 56 6
Ischemic Cerebrovascular Accident 71
Stroke, Susceptibility to 56
Cva - Cerebral Infarction 12
Cerebral Infarct 12
Ischstr 73

Characteristics:

OMIM:

56
Inheritance:
multifactorial predisposition


Classifications:

MalaCards categories:
Global: Genetic diseases Metabolic diseases
Anatomical: Cardiovascular diseases Neuronal diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:3526
OMIM 56 601367
MeSH 43 D002544
NCIt 49 C50486
SNOMED-CT 67 20059004
SNOMED-CT via HPO 68 230690007
UMLS 71 C0007785 C0038454 C0948008 more
Sources

Summaries for Stroke, Ischemic

About this section
MedlinePlus : 42 What is a stroke? A stroke happens when there is a loss of blood flow to part of the brain. Your brain cells cannot get the oxygen and nutrients they need from blood, and they start to die within a few minutes. This can cause lasting brain damage, long-term disability, or even death. If you think that you or someone else is having a stroke, call 911 right away. Immediate treatment may save someone's life and increase the chances for successful rehabilitation and recovery. What are the types of stroke? There are two types of stroke: Ischemic stroke is caused by a blood clot that blocks or plugs a blood vessel in the brain. This is the most common type; about 80 percent of strokes are ischemic. Hemorrhagic stroke is caused by a blood vessel that breaks and bleeds into the brain Another condition that's similar to a stroke is a transient ischemic attack (TIA). It's sometimes called a "mini-stroke." TIAs happen when the blood supply to the brain is blocked for a short time. The damage to the brain cells isn't permanent, but if you have had a TIA, you are at a much higher risk of having a stroke. Who is at risk for a stroke? Certain factors can raise your risk of a stroke. The major risk factors include High blood pressure. This is the primary risk factor for a stroke. Diabetes. Heart diseases. Atrial fibrillation and other heart diseases can cause blood clots that lead to stroke. Smoking. When you smoke, you damage your blood vessels and raise your blood pressure. A personal or family history of stroke or TIA. Age. Your risk of stroke increases as you get older. Race and ethnicity. African Americans have a higher risk of stroke. There are also other factors that are linked to a higher risk of stroke, such as Alcohol and illegal drug use Not getting enough physical activity High cholesterol Unhealthy diet Having obesity What are the symptoms of stroke? The symptoms of stroke often happen quickly. They include Sudden numbness or weakness of the face, arm, or leg (especially on one side of the body) Sudden confusion, trouble speaking, or understanding speech Sudden trouble seeing in one or both eyes Sudden difficulty walking, dizziness, loss of balance or coordination Sudden severe headache with no known cause If you think that you or someone else is having a stroke, call 911 right away. How are strokes diagnosed? To make a diagnosis, your health care provider will Ask about your symptoms and medical history Do a physical exam, including a check of Your mental alertness Your coordination and balance Any numbness or weakness in your face, arms, and legs Any trouble speaking and seeing clearly Run some tests, which may include Diagnostic imaging of the brain, such as a CT scan or MRI Heart tests, which can help detect heart problems or blood clots that may have led to a stroke. Possible tests include an electrocardiogram (EKG) and an echocardiography. What are the treatments for stroke? Treatments for stroke include medicines, surgery, and rehabilitation. Which treatments you get depend on the type of stroke and the stage of treatment. The different stages are Acute treatment, to try to stop a stroke while it is happening Post-stroke rehabilitation, to overcome the disabilities caused by the stroke Prevention, to prevent a first stroke or, if you have already had one, prevent another stroke Acute treatments for ischemic stroke are usually medicines: You may get tPA, (tissue plasminogen activator), a medicine to dissolve the blood clot. You can only get this medicine within 4 hours of when your symptoms started. The sooner you can get it, the better your chance of recovery. If you cannot get that medicine, you may get medicine that helps stop platelets from clumping together to form blood clots. Or you may get a blood thinner to keep existing clots from getting bigger. If you have carotid artery disease, you may also need a procedure to open your blocked carotid artery Acute treatments for hemorrhagic stroke focus on stopping the bleeding. The first step is to find the cause of bleeding in the brain. The next step is to control it: If high blood pressure is the cause of bleeding, you may be given blood pressure medicines. If an aneurysm if the cause, you may need aneurysm clipping or coil embolization. These are surgeries to prevent further leaking of blood from the aneurysm. It also can help prevent the aneurysm from bursting again. If an arteriovenous malformation (AVM) is the cause of a stroke, you may need an AVM repair. An AVM is a tangle of faulty arteries and veins that can rupture within the brain. An AVM repair may be done through Surgery Injecting a substance into the blood vessels of the AVM to block blood flow Radiation to shrink the blood vessels of the AVM Stroke rehabilitation can help you relearn skills you lost because of the damage. The goal is to help you become as independent as possible and to have the best possible quality of life. Prevention of another stroke is also important, since having a stroke increases the risk of getting another one. Prevention may include heart-healthy lifestyle changes and medicines. Can strokes be prevented? If you have already had a stroke or are at risk of having a stroke, you can make some heart-healthy lifestyle changes to try to prevent a future stroke: Eating a heart-healthy diet Aiming for a healthy weight Managing stress Getting regular physical activity Quitting smoking Managing your blood pressure and cholesterol levels If these changes aren't enough, you may need medicine to control your risk factors. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Stroke, Ischemic, also known as cerebral infarction, is related to sneddon syndrome and retinal vascular occlusion, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Stroke, Ischemic is PRKCH (Protein Kinase C Eta), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Folate Metabolism. The drugs Ticlopidine and Nadroparin have been mentioned in the context of this disorder. Affiliated tissues include Bone and Brain, and related phenotypes are stroke and homeostasis/metabolism

Disease Ontology : 12 A cerebrovascular disease that is characterized by an area of necrotic tissue in the brain resulting from a blockage or narrowing in the arteries supplying blood and oxygen to the brain.

OMIM : 56 A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. It is said to be the third leading cause of death in the United States. Gunel and Lifton (1996) noted that about 20% of strokes are hemorrhagic, resulting in bleeding into the brain. Ischemic strokes, resulting from vascular occlusion, account for the majority of strokes. Bersano et al. (2008) reviewed genetic polymorphisms that have been implicated in the development of stroke. Candidate genes include those involved in hemostasis (see, e.g., F5; 612309), the renin-angiotensin-aldosterone system (see, e.g., ACE; 106180), homocysteine (see, e.g., MTHFR; 607093), and lipoprotein metabolism (see, e.g., APOE; 107741). See also hemorrhagic stroke, or intracerebral hemorrhage (ICH; 614519). (601367)

CDC : 3 A stroke, sometimes called a brain attack, occurs when something blocks blood supply to part of the brain or when a blood vessel in the brain bursts. In either case, parts of the brain become damaged or die. A stroke can cause lasting brain damage, long-term disability, or even death. Learn more about what causes stroke and what happens during a stroke.

NINDS : 53 A stroke occurs when the blood supply to part of the brain is suddenly interrupted or when a blood vessel in the brain bursts, spilling blood into the spaces surrounding brain cells. Brain cells die when they no longer receive oxygen and nutrients from the blood or there is sudden bleeding into or around the brain. The symptoms of a stroke include sudden numbness or weakness, especially on one side of the body; sudden confusion or trouble speaking or understanding speech; sudden trouble seeing in one or both eyes; sudden trouble with walking, dizziness, or loss of balance or coordination; or sudden severe headache with no known cause. There are two forms of stroke: ischemic - blockage of a blood vessel supplying the brain, and hemorrhagic - bleeding into or around the brain.

UniProtKB/Swiss-Prot : 73 Ischemic stroke: A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.

PubMed Health : 62 About stroke: A stroke occurs if the flow of oxygen-rich blood to a portion of the brain is blocked. Without oxygen, brain cells start to die after a few minutes. Sudden bleeding in the brain also can cause a stroke if it damages brain cells. If brain cells die or are damaged because of a stroke, symptoms occur in the parts of the body that these brain cells control. Examples of stroke symptoms include sudden weakness; paralysis or numbness of the face, arms, or legs (paralysis is an inability to move); trouble speaking or understanding speech; and trouble seeing. A stroke is a serious medical condition that requires emergency care. A stroke can cause lasting brain damage, long-term disability, or even death. If you think you or someone else is having a stroke, call 9–1–1 right away. Do not drive to the hospital or let someone else drive you. Call an ambulance so that medical personnel can begin life-saving treatment on the way to the emergency room. During a stroke, every minute counts.

Sources

Related Diseases for Stroke, Ischemic

About this section

Diseases related to Stroke, Ischemic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2227)
# Related Disease Score Top Affiliating Genes
1 sneddon syndrome 35.3 SERPINC1 F5 F2 APOH
2 retinal vascular occlusion 33.4 SERPINC1 MTHFR F5 F2 APOH
3 buerger disease 33.1 NOS3 MTHFR F2 APOH
4 carotid artery occlusion 33.0 PLAT NOS3 LDLR F5 APOH
5 cerebrovascular disease 32.7 PLAT NOTCH3 MTHFR LDLR F5 F2
6 behcet syndrome 32.7 SERPINC1 MTHFR F5 F2 APOH ACE
7 col4a1-related familial vascular leukoencephalopathy 32.3 NOTCH3 MT-TL1
8 myocardial infarction 32.2 SERPINC1 PLAT NOS3 MTHFR MIAT LDLR
9 cardiovascular system disease 32.0 SERPINC1 PLAT NOS3 MTHFR LDLR F3
10 cerebral sinovenous thrombosis 31.9 MTHFR F5 F3 F2 APOH
11 pulmonary embolism 31.9 SERPINC1 PLAT MTHFR F5 F3 F2
12 peripheral vascular disease 31.9 SERPINC1 PLAT NOS3 F5 F3 F2
13 intracranial thrombosis 31.9 SERPINC1 PLAT MTHFR F5 F3 F2
14 thrombosis 31.8 SERPINC1 PLAT NOS3 MTHFR F5 F3
15 thrombophilia due to thrombin defect 31.8 SERPINC1 PLAT MTHFR F5 F3 F2
16 hypercholesterolemia, familial, 1 31.8 NOS3 LDLR ACE
17 intracranial embolism 31.7 SERPINC1 PLAT F3 F2 ACE
18 thrombophilia 31.7 SERPINC1 PLAT MTHFR F5 F3 F2
19 atrial heart septal defect 31.7 SERPINC1 PLAT MTHFR FBN1 F3 F2
20 diabetes mellitus 31.7 SERPINC1 PLAT PIK3CA NOS3 MTHFR MT-TL1
21 coronary heart disease 1 31.7 PLAT NOS3 MTHFR LDLR CDKN2B-AS1 ACE
22 sickle cell anemia 31.6 NOS3 MTHFR F2
23 retinal artery occlusion 31.6 SERPINC1 MTHFR F5 F2 APOH ACE
24 hypertension, essential 31.5 SERPINC1 PLAT NOS3 MTHFR LDLR FBN1
25 branch retinal artery occlusion 31.5 SERPINC1 MTHFR F3 F2
26 peripheral artery disease 31.5 NOS3 F3 CDKN2B-AS1 ACE
27 angina pectoris 31.5 PLAT NOS3 F3 ACE
28 migraine with aura 31.5 NOTCH3 NOS3 MTHFR F2 ACE
29 nephrosclerosis 31.5 MTHFR F3 F2 ACE
30 intracranial hypertension 31.5 SERPINC1 MTHFR F5 F3 F2 APOH
31 splenic infarction 31.5 SERPINC1 F3 F2 APOH
32 atherosclerosis susceptibility 31.5 PLAT NOS3 MTHFR LDLR F3 CDKN2B-AS1
33 antithrombin iii deficiency 31.4 SERPINC1 MTHFR F5 F2 APOH
34 protein c deficiency 31.4 SERPINC1 MTHFR F5 F2 APOH
35 coronary artery anomaly 31.4 SERPINC1 PLAT NOS3 F3 F2 ACE
36 intermediate coronary syndrome 31.4 SERPINC1 PLAT F3 ACE
37 vascular dementia 31.4 NOTCH3 MTHFR ACE
38 heart valve disease 31.4 FBN1 F3 F2 APOH ACE
39 hemopericardium 31.4 FBN1 F3 F2
40 central retinal artery occlusion 31.4 SERPINC1 PLAT F2
41 carotid artery disease 31.4 PLAT F3 ACE
42 intermittent claudication 31.4 SERPINC1 F2 APOH ACE
43 placenta disease 31.4 SERPINC1 MTHFR F5 F3 F2 APOH
44 moyamoya disease 1 31.4 SERPINC1 MTHFR F3 F2
45 homocystinuria 31.4 SERPINC1 MTHFR FBN1 F5
46 homocysteinemia 31.4 SERPINC1 NOS3 MTHFR FBN1 F5 F2
47 cerebral palsy 31.4 NOS3 MTHFR F5 F2
48 transient cerebral ischemia 31.4 NOTCH3 MTHFR APOH
49 familial hypercholesterolemia 31.4 NOS3 MTHFR LDLR F2 ACE
50 limb ischemia 31.3 PLAT NOS3 F2 ACE

Graphical network of the top 20 diseases related to Stroke, Ischemic:



Diseases related to Stroke, Ischemic
Sources

Symptoms & Phenotypes for Stroke, Ischemic

About this section

Human phenotypes related to Stroke, Ischemic:

31
# Description HPO Frequency HPO Source Accession
1 stroke 31 HP:0001297

Symptoms via clinical synopsis from OMIM:

56
Neuro:
stroke
motor, sensory and/or cognitive function loss

Clinical features from OMIM:

601367

UMLS symptoms related to Stroke, Ischemic:


seizures, tremor, angina pectoris, edema, chest pain, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness

MGI Mouse Phenotypes related to Stroke, Ischemic:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ACE ACSL4 ALOX5AP APOH F2 F3
2 cardiovascular system MP:0005385 10.29 ACE ACSL4 F2 F3 F5 FBN1
3 growth/size/body region MP:0005378 10.29 ACE ACSL4 F2 F3 F5 FBN1
4 hematopoietic system MP:0005397 10.23 ACE ACSL4 ALOX5AP F2 F3 FBN1
5 mortality/aging MP:0010768 10.2 ACE ACSL4 APOH F2 F3 F5
6 immune system MP:0005387 10.18 ACE ALOX5AP F2 F3 FBN1 LDLR
7 endocrine/exocrine gland MP:0005379 10.15 ACE ACSL4 FBN1 LDLR NOS3 NOTCH3
8 integument MP:0010771 10.07 F2 F3 F5 FBN1 LDLR MTHFR
9 nervous system MP:0003631 10.03 F2 F3 F5 FBN1 LDLR MTHFR
10 reproductive system MP:0005389 9.85 ACE ACSL4 F2 FBN1 MTHFR NOS3
11 skeleton MP:0005390 9.61 ACSL4 ALOX5AP F2 FBN1 MTHFR NOS3
12 vision/eye MP:0005391 9.28 F3 LDLR MTHFR NOS3 NOTCH3 PIK3CA
Sources

Drugs & Therapeutics for Stroke, Ischemic

About this section

PubMed Health treatment related to Stroke, Ischemic: 62

Treatment for a stroke depends on whether it is ischemic or hemorrhagic. Treatment for a transient ischemic attack (TIA) depends on its cause, how much time has passed since symptoms began, and whether you have other medical conditions. Strokes and TIAs are medical emergencies. If you have stroke symptoms, call 9–1–1 right away. Do not drive to the hospital or let someone else drive you. Call an ambulance so that medical personnel can begin life-saving treatment on the way to the emergency room. During a stroke, every minute counts. Once you receive initial treatment , your doctor will try to treat your stroke risk factors and prevent complications.

Drugs for Stroke, Ischemic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4 55142-85-3 5472
2
Nadroparin Approved, Investigational Phase 4
3
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
4
Glyburide Approved Phase 4 10238-21-8 3488
5
Ustekinumab Approved, Investigational Phase 4 815610-63-0
6
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
Alogliptin Approved Phase 4 850649-61-5 11450633
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
11
Edaravone Approved, Investigational Phase 4 89-25-8 70335
12
Abciximab Approved Phase 4 143653-53-6
13
Ezetimibe Approved Phase 4 163222-33-1 150311
14
Enoxaparin Approved Phase 4 9005-49-6 772
15
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
16
Triflusal Approved, Investigational Phase 4 322-79-2
17
Dipyridamole Approved Phase 4 58-32-2 3108
18
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
19
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
20
Pantoprazole Approved Phase 4 102625-70-7 4679
21
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
22
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
23
Reteplase Approved, Investigational Phase 4 133652-38-7 65820
24
Tirofiban Approved Phase 4 144494-65-5 60947
25
Phenindione Approved, Investigational Phase 4 83-12-5 4760
26
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
27
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
28
Insulin aspart Approved Phase 4 116094-23-6 16132418
29
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
30
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
31
Galantamine Approved Phase 4 357-70-0 9651
32
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
33
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
34
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
35
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
36
Quinidine Approved, Investigational Phase 4 56-54-2 441074
37
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
38
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
39
Bevacizumab Approved, Investigational Phase 4 216974-75-3
40
acetic acid Approved Phase 4 64-19-7 176
41
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
42
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
43
Ranibizumab Approved Phase 4 347396-82-1 459903
44
Gliclazide Approved Phase 4 21187-98-4 3475
45
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
46
Propafenone Approved Phase 4 54063-53-5 4932
47
Haloperidol Approved Phase 4 52-86-8 3559
48
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
49
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
50
Ziprasidone Approved Phase 4 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 9488)
# Name Status NCT ID Phase Drugs
1 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
2 Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
3 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
4 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
5 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
6 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
7 The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
8 A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
9 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
10 Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
11 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
12 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
13 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
14 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
15 A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism Unknown status NCT03090113 Phase 4 Shuxuetong Injection;Placebo Injection
16 Study of Influence of Timing on Motor Learning Unknown status NCT02048826 Phase 4
17 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
18 The Impact of Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Evaluated by Computed Tomography Perfusion (CTP) Unknown status NCT02594800 Phase 4 Rosuvastatin
19 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
20 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
21 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
22 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
23 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
24 Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Unknown status NCT01906749 Phase 4 Colchicine;Placebo
25 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
26 A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis Unknown status NCT01553643 Phase 4 Chinese Herb Huang-Chi-Wu-Wu-Tang;placebo
27 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
28 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
29 Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging in Two Years Unknown status NCT02041117 Phase 4 Rosuvastatin
30 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients Unknown status NCT02484027 Phase 4 Rosuvastatin
31 The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels Unknown status NCT01926834 Phase 4 Erigeron Injection;placebo
32 A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH) Unknown status NCT00699465 Phase 4 enoxaparin;enoxaparin placebo
33 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
34 Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident Unknown status NCT02714478 Phase 4
35 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
36 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
37 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
38 Effects of the Use of "de Novo" Everolimus for the Expression of Cytokines in Kidneys From Extended Criteria Donors and With Delayed Graft Function Unknown status NCT01663805 Phase 4 Everolimus
39 Azelnidipine vs Perindopril and Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients (APPROVE):Multi-center Randomized Controlled Clinical Trial Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
40 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
41 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
42 Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study Unknown status NCT01955200 Phase 4 Ticagrelor;Clopidogrel;Cilostazol;Clopidogrel;Clopidogrel
43 SCARF: Saxagliptin on CArdiac StRucture and Function Unknown status NCT02481479 Phase 4 Saxagliptin;Saxagliptin;saxagliptin
44 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
45 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
46 Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome Unknown status NCT02604654 Phase 4 Yiqitongluo granule
47 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
48 Reducing Blood Loss During Total Knee Arthroplasty Using Tisseel: A Prospective Randomized Control Trial Unknown status NCT03310060 Phase 4 Tisseel;Tranexamic Acid
49 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
50 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide

Search NIH Clinical Center for Stroke, Ischemic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dantrolene
Dantrolene Sodium
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Stroke, Ischemic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Stroke, Ischemic:
Umbilical cord blood-derived CD34+ stem cells for treatment of chronic ischemic stroke
NSI-566, spinal cord stem cells for neurological disorders
Bone marrow-derived mononuclear cells for ischemic stroke
MultiStem, bone marrow-derived cells for ischemic and neonatal stroke
ALD-401, bone marrow-derived cells for stroke
Cerecellgram-Stroke, bone marrow-derived mesenchymal stem cells for treatment of ischemic stroke
SB623, Notch1-transfected mesenchymal stem cells for stroke
Stemedyne-MSC, mesenchymal stem cells for ischemic stroke
Umbilical cord-derived mesenchymal stem cells for treatment of stroke
Autologous bone marrow-derived mononuclear cells for treatment of acute ischemic stroke
Mesenchymal stem cells for ischemic stroke
Mesenchymal stem cell-derived neuronal progenitor cells for the treatment of ischemic brain damage
ReN001, human neural stem cells for the treatment of stroke
PDA001, Placenta-derived cells for ischemic stroke
Embryonic stem cell-derived neural stem cells for ischemic stroke
Olfactory ensheathing cells transplantion for treatment of old stroke ischemic patients
Bone marrow-derived mononuclear cells for ischemic stroke
Embryonic/Adult Cultured Cells Related to Stroke, Ischemic:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905
Bone marrow-derived mononuclear cells (family) PMIDs: 22960888
Bone marrow-derived mononuclear cells PMIDs: 17635049
Bone marrow-derived mononuclear cells PMIDs: 20395386 20629187
Neural stem cells PMIDs: 18286199
Neural progenitor cells PMIDs: 21300404
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 22952736 21175285
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Neural stem cell line (CTX0E03) PMIDs: 19633272 23185625 17981710
Notch-transfected mesenchymal stromal cells (SB623) PMIDs: 19530164 23430693 20350349 21982515
Trophic factor-induced mesenchymal stem cells PMIDs: 19530164 23430693 20350349 21982515
Bone marrow-derived mesenchymal stem cells (Stemedyne-MSC, itMSC) PMIDs: 23295150
Bone marrow-derived mesenchymal stem cells (Cerecellgram-Stroke)
Bone marrow-derived mesenchymal stem cells (family)
Olfactory ensheathing cells
Umbilical cord-derived mesenchymal stem cells
Umbilical cord blood-derived hematopoietic stem cells (family)
Placenta-derived cells

Cochrane evidence based reviews: cerebral infarction

Sources

Genetic Tests for Stroke, Ischemic

About this section

Genetic tests related to Stroke, Ischemic:

# Genetic test Affiliating Genes
1 Ischemic Stroke 29 ALOX5AP PRKCH
2 Stroke, Ischemic, Susceptibility to 29
Sources

Anatomical Context for Stroke, Ischemic

About this section

MalaCards organs/tissues related to Stroke, Ischemic:

40
Brain, Heart, Testes, Endothelial, Kidney, Bone, Spinal Cord
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Stroke, Ischemic:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate
Sources

Publications for Stroke, Ischemic

About this section

Articles related to Stroke, Ischemic:

(show top 50) (show all 32139)
# Title Authors PMID Year
1
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 54 56 6
15534175 2004
2
The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. 56 6
17165044 2007
3
A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. 56 6
17206144 2007
4
A functional variant in the 3'-UTR of angiopoietin-1 might reduce stroke risk by interfering with the binding efficiency of microRNA 211. 54 56
20378606 2010
5
Failure to validate association between 12p13 variants and ischemic stroke. 61 56
20410525 2010
6
Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke. 61 56
20042462 2010
7
Genomewide association studies of stroke. 61 56
19369658 2009
8
Genetic polymorphisms for the study of multifactorial stroke. 61 56
18421701 2008
9
Linking Notch signaling to ischemic stroke. 61 56
18347334 2008
10
Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. 54 56
16550187 2006
11
Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. 54 56
16286536 2006
12
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. 54 56
16115816 2005
13
Association of the metabolic syndrome with intracranial atherosclerotic stroke. 61 56
16043803 2005
14
Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. 54 56
15640973 2005
15
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 54 6
15277638 2004
16
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. 54 56
14770184 2004
17
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. 54 56
14681304 2004
18
Genetics of common polygenic stroke. 61 56
14517535 2003
19
New players in the genetics of stroke. 61 56
12444190 2002
20
Vascular effects of statins in stroke. 61 56
9368582 1997
21
A study of twins and stroke. 61 56
1561651 1992
22
Causes of Acute Stroke: A Patterned Approach. 61 42
31582037 2019
23
Perfusion Computed Tomography in Acute Ischemic Stroke. 61 42
31582038 2019
24
Predictors of prolonged hospital stay in a Comprehensive Stroke Unit. 61 42
31618390 2019
25
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. 6
25355838 2014
26
Association study of the polymorphisms on chromosome 12p13 with atherothrombotic stroke in the Japanese population. 56
20448654 2010
27
Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. 6
19531787 2009
28
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 6
19221299 2009
29
Genetically elevated C-reactive protein and ischemic vascular disease. 56
18971492 2008
30
Telomere length predicts poststroke mortality, dementia, and cognitive decline. 56
16685698 2006
31
Genetic association between endothelial nitric oxide synthase and Alzheimer disease. 6
16813604 2006
32
Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. 6
16493002 2006
33
R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation. 6
15638861 2005
34
The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. 6
16059745 2005
35
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 6
15635071 2005
36
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 6
15531537 2004
37
ACE1 polymorphism and progression of SARS. 6
15381116 2004
38
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 6
15110771 2004
39
Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. 6
15007011 2004
40
Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. 6
14996674 2004
41
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 6
14872014 2004
42
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 6
14657821 2003
43
Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. 6
12958323 2003
44
Phenotype modulators in myophosphorylase deficiency. 6
12666117 2003
45
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 6
12220450 2002
46
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. 6
11956052 2002
47
Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. 6
11796466 2002
48
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. 6
11687636 2001
49
Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden--an evolutionary advantage? 6
11686338 2001
50
Endothelial nitric oxide synthase gene (NOS3) variant and hypertension in pregnancy. 6
11745998 2001